Here, we report that the SMN2 splicing modifier NVS-SM2 is highly active in vivo and could be titrated in dosage, timing, and duration of administration for the development of robust SMA mouse models with varying stages of disease. Here, SMN2 is linked to proximal spinal muscular atrophy.